CN104825483B - 一种丙磺舒缓释片及制备方法 - Google Patents
一种丙磺舒缓释片及制备方法 Download PDFInfo
- Publication number
- CN104825483B CN104825483B CN201510275322.1A CN201510275322A CN104825483B CN 104825483 B CN104825483 B CN 104825483B CN 201510275322 A CN201510275322 A CN 201510275322A CN 104825483 B CN104825483 B CN 104825483B
- Authority
- CN
- China
- Prior art keywords
- sustained release
- parts
- probenecid
- release tablets
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 229960003081 probenecid Drugs 0.000 title claims abstract description 72
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000011248 coating agent Substances 0.000 claims abstract description 51
- 238000000576 coating method Methods 0.000 claims abstract description 51
- 239000008188 pellet Substances 0.000 claims abstract description 45
- 239000000463 material Substances 0.000 claims abstract description 42
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 33
- 238000013268 sustained release Methods 0.000 claims abstract description 28
- 239000012730 sustained-release form Substances 0.000 claims abstract description 28
- 239000004014 plasticizer Substances 0.000 claims abstract description 27
- 239000004088 foaming agent Substances 0.000 claims abstract description 19
- 239000000314 lubricant Substances 0.000 claims abstract description 19
- 239000007884 disintegrant Substances 0.000 claims abstract description 18
- 239000000945 filler Substances 0.000 claims abstract description 18
- 239000002775 capsule Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 13
- -1 tabletting Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 19
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000012047 saturated solution Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 235000019890 Amylum Nutrition 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000004425 Makrolon Substances 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 210000003516 pericardium Anatomy 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 8
- 201000005569 Gout Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000001684 chronic effect Effects 0.000 abstract description 6
- 229930182555 Penicillin Natural products 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 206010007027 Calculus urinary Diseases 0.000 abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 4
- 208000009911 Urinary Calculi Diseases 0.000 abstract description 4
- 210000001635 urinary tract Anatomy 0.000 abstract description 4
- 150000002960 penicillins Chemical class 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 230000001458 anti-acid effect Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 210000004051 gastric juice Anatomy 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 11
- 201000001431 Hyperuricemia Diseases 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000005864 Sulphur Substances 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical class N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229930186147 Cephalosporin Chemical class 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 229940121792 Thiazide diuretic Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000002109 interictal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510275322.1A CN104825483B (zh) | 2015-05-26 | 2015-05-26 | 一种丙磺舒缓释片及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510275322.1A CN104825483B (zh) | 2015-05-26 | 2015-05-26 | 一种丙磺舒缓释片及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104825483A CN104825483A (zh) | 2015-08-12 |
CN104825483B true CN104825483B (zh) | 2017-10-13 |
Family
ID=53803938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510275322.1A Active CN104825483B (zh) | 2015-05-26 | 2015-05-26 | 一种丙磺舒缓释片及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104825483B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105168466A (zh) * | 2015-09-15 | 2015-12-23 | 青岛海之源智能技术有限公司 | 一种氟康唑复方缓释片及其制备方法 |
CN105126031A (zh) * | 2015-09-25 | 2015-12-09 | 青岛海之源智能技术有限公司 | 一种头孢氨苄复方缓释片及其制备方法 |
CN105194452A (zh) * | 2015-10-29 | 2015-12-30 | 青岛海之源智能技术有限公司 | 一种盐酸伐昔洛韦复方缓释片及其制备方法 |
CN105214052A (zh) * | 2015-10-29 | 2016-01-06 | 青岛海之源智能技术有限公司 | 一种用于手癣的咪康唑复方缓释片及其制备方法 |
CN105311273A (zh) * | 2015-11-26 | 2016-02-10 | 青岛海之源智能技术有限公司 | 一种法莫替丁复方缓释片及其制备方法 |
CN108785268B (zh) * | 2018-01-17 | 2021-05-28 | 威海华新药业集团有限公司 | 一种盐酸索他洛尔制剂及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE266407T1 (de) * | 2000-10-30 | 2004-05-15 | Lupin Ltd | Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe |
CN1698896A (zh) * | 2005-05-30 | 2005-11-23 | 西安交通大学 | 注射用复方β-内酰胺类钠盐/丙磺舒钠的制备方法 |
CN101926794A (zh) * | 2009-06-23 | 2010-12-29 | 天津泰普药品科技发展有限公司 | 一种用于治疗痛风的药物组合物 |
-
2015
- 2015-05-26 CN CN201510275322.1A patent/CN104825483B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104825483A (zh) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104825483B (zh) | 一种丙磺舒缓释片及制备方法 | |
WO2013054872A1 (ja) | 7-[4-(4-ベンゾ[b]チオフェン-4-イル-ピペラジン-1-イル)ブトキシ]-1H-キノリン-2-オン又はその塩を含む錠剤 | |
CN1607947A (zh) | 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物 | |
CN106074445B (zh) | 包衣药物球状体及其制备消除或减少病症的药物的用途 | |
CN101574323B (zh) | 一种米格列醇微囊片剂及其制备方法 | |
CN107249590A (zh) | 固体制剂 | |
CN105287411A (zh) | 一种吡仑帕奈分散片及其制备方法 | |
CN102512393A (zh) | 一种托伐普坦的口腔崩解片 | |
CN103908443A (zh) | 一种盐酸普罗帕酮缓释胶囊及其制备方法 | |
CN102441019B (zh) | 一种中药菊花口含片 | |
CN102451162A (zh) | 经口腔粘膜吸收的奥氮平药物 | |
CN108066312B (zh) | 一种帕博西尼药物组合物及其制备方法 | |
CN102309562B (zh) | 葛根芩连汤掩味混悬颗粒剂的制备方法 | |
CN112426408A (zh) | 一种褪黑素组合物及其制备工艺 | |
CN110251473A (zh) | 羟哌吡酮口服缓释制剂 | |
JPWO2017047586A1 (ja) | 錠剤 | |
CN105687157A (zh) | 一种盐酸左氧氟沙星胶囊及其制备方法 | |
CN1443535A (zh) | 马来酸替加色罗口服制剂及其制备工艺——治疗肠易惹综合征 | |
CN101961319B (zh) | 一种高生物利用度的水飞蓟宾葡甲胺肠溶制剂及其制备方法 | |
CN105267172B (zh) | 简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法 | |
CN104856975A (zh) | 一种丙磺舒缓释胶囊及制备方法 | |
CN101375852B (zh) | 富马酸喹硫平口服制剂及其制备方法 | |
US20120029048A1 (en) | Phenylalkyl n-hydroxyureas for treating leukotriene related pathologies | |
CN103536580B (zh) | 一种银杏提取物延迟脉冲胶囊及其质量控制方法 | |
CN114376978B (zh) | 一种多索茶碱包芯片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200624 Address after: No. 208, No. 288-1, Bole Road, high tech Zone, Jinan City, Shandong Province Patentee after: SHANDONG ZHIDAO INTELLECTUAL PROPERTY MANAGEMENT Co.,Ltd. Address before: Ying Hai Building No. 12 266061 Shandong city of Qingdao province Laoshan area Xiangshan Road Patentee before: QINGDAO HAIZHIXING BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201120 Address after: 223299 Building 1, Xingyu Huafu, Meigao Road, eco Cultural Tourism District, Huai'an City, Jiangsu Province, 2008 Patentee after: Li Chao Address before: No. 208, No. 288-1, Bole Road, high tech Zone, Jinan City, Shandong Province Patentee before: SHANDONG ZHIDAO INTELLECTUAL PROPERTY MANAGEMENT Co.,Ltd. |